Jade Biosciences
JBIO
59 hedge funds and large institutions have $488M invested in Jade Biosciences in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 23 increasing their positions, 13 reducing their positions, and 8 closing their positions.
77% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 13
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
0.04% less ownership
Funds ownership: 2.99% → 2.95% (-0.04%)
7% less capital invested
Capital invested by funds: $524M → $488M (-$35.8M)
8% less funds holding
Funds holding: 64 → 59 (-5)
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$21.8M |
| 2 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$20.5M |
| 3 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$12M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$5.33M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$3.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
-$16.8M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
-$3.94M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.39M |
| 4 |
FAM
Fred Alger Management
New York
|
-$844K |
| 5 |
BFM
Boothbay Fund Management
New York
|
-$798K |
JBIO Hedge Fund Activity: Q2 2023 in Review
59 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Jade Biosciences (JBIO) for Q2 2023, worth a combined $488M — down 6.8% from $524M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of JBIO and 3 opened new positions — a net loss of 5 holders — while 13 trimmed existing stakes and 23 added.
The largest buyer was Driehaus Capital Management, opening a new position worth an estimated $21.8M. The largest seller was VR Adviser, exiting entirely with an estimated $16.8M sold.
- 59 institutional investors held Jade Biosciences (JBIO) as of Q2 2023, down from 64 in Q1 2023.
- Funds reported $488M of Jade Biosciences stock for Q2 2023, down 6.8% quarter-over-quarter.
- 3 funds opened new Jade Biosciences positions in Q2 2023 and 8 closed out, a net change of -5 holders.
- The largest Jade Biosciences buyer in Q2 2023 was Driehaus Capital Management, an estimated $21.8M added.
- The largest Jade Biosciences seller in Q2 2023 was VR Adviser, an estimated $16.8M sold.
Based on aggregated 13F filings for Q2 2023.